Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Gkotzamanidou

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Critical Reviews in Oncology/Hematology|October 1, 2013
Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantationMaria Gkotzamanidou, Christos A Papadimitriou
International Journal of Molecular Sciences|October 13, 2021
Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma TherapyMaria Gkotzamanidou, Elisavet Terpou, Nikolaos Kentepozidis, et al.
International Journal of Molecular Sciences|December 23, 2022
The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple MyelomaMaria Gkotzamanidou, Evangelos Terpos, Meletios A Dimopoulos, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|December 21, 2013
Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myelomaMaria Gkotzamanidou, Dimitrios Christoulas, Vasillis L Souliotis, et al.
Expert Opinion on Therapeutic Targets|July 6, 2012
Sclerostin: a possible target for the management of cancer-induced bone diseaseMaria Gkotzamanidou, Meletios A Dimopoulos, Efstathios Kastritis, et al.
Expert Opinion on Therapeutic Targets|June 18, 2009
Dickkopf-1: a suitable target for the management of myeloma bone diseaseMaria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Dimitrios Christoulas, et al.
Blood|July 23, 2016
DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7Maria Gkotzamanidou, Evangelos Terpos, Christina Bamia, et al.
Leukemia & Lymphoma|December 7, 2011
Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimensEvangelos Eleftherakis-Papapiakovou, Esftathios Kastritis, Maria Roussou, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Expression of CCL3 by neoplastic cells in patients with Waldenström's macroglobulinemia: an immunohistochemical study in bone marrow biopsies of 67 patientsEvangelos Terpos, Anna Tasidou, Evangelos Eleftherakis-Papaiakovou, et al.
European Journal of Haematology|June 3, 2011
Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapyMagdalini Migkou, Efstathios Kastritis, Maria Roussou, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Critical Reviews in Oncology/Hematology|October 1, 2013
Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantationMaria Gkotzamanidou, Christos A Papadimitriou
International Journal of Molecular Sciences|October 13, 2021
Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma TherapyMaria Gkotzamanidou, Elisavet Terpou, Nikolaos Kentepozidis, et al.
International Journal of Molecular Sciences|December 23, 2022
The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple MyelomaMaria Gkotzamanidou, Evangelos Terpos, Meletios A Dimopoulos, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|December 21, 2013
Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myelomaMaria Gkotzamanidou, Dimitrios Christoulas, Vasillis L Souliotis, et al.
Expert Opinion on Therapeutic Targets|July 6, 2012
Sclerostin: a possible target for the management of cancer-induced bone diseaseMaria Gkotzamanidou, Meletios A Dimopoulos, Efstathios Kastritis, et al.
Expert Opinion on Therapeutic Targets|June 18, 2009
Dickkopf-1: a suitable target for the management of myeloma bone diseaseMaria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Dimitrios Christoulas, et al.
Blood|July 23, 2016
DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7Maria Gkotzamanidou, Evangelos Terpos, Christina Bamia, et al.
Leukemia & Lymphoma|December 7, 2011
Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimensEvangelos Eleftherakis-Papapiakovou, Esftathios Kastritis, Maria Roussou, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Expression of CCL3 by neoplastic cells in patients with Waldenström's macroglobulinemia: an immunohistochemical study in bone marrow biopsies of 67 patientsEvangelos Terpos, Anna Tasidou, Evangelos Eleftherakis-Papaiakovou, et al.
European Journal of Haematology|June 3, 2011
Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapyMagdalini Migkou, Efstathios Kastritis, Maria Roussou, et al.
Pageof 3